The data is published in Surgical Innovation: Advances in Minimally Invasive Surgical Science, Technology, and Training.
Here’s what you should know:
1. These results are the longest available follow-up data from randomized controlled trials concerning the TIF 2.0 procedure.
2. Five-year follow-up data was provided by 44 of the original 63 patients.
3. In the study, all primary endpoints were met, with 86 percent of patients reporting no regurgitation and 80 percent of patients reporting no atypical symptoms.
4. The procedure also improved health-related quality of life scores and patient satisfaction among GERD patients.
More articles on gastroenterology:
UroLife designates Midtown Urology Associates a UroLife Center of Excellence: 3 insights
The definition of ‘outpatient’ ACDF and lumbar discectomy procedures can be misleading: 5 insights
Senate report: 5 opioid manufacturers paid $9M to 14 patient advocacy groups — 8 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.